Tonix Pharmaceuticals (NASDAQ:TNXP) Posts Quarterly Earnings Results, Beats Estimates By $1.80 EPS

Tonix Pharmaceuticals (NASDAQ:TNXP) issued its earnings results on Tuesday. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80, Zacks reports. The business had revenue of $2.82 million for the quarter, compared to the consensus estimate of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 158.64%.

Tonix Pharmaceuticals Stock Performance

Shares of NASDAQ:TNXP traded down $0.00 on Thursday, reaching $0.14. 4,763,976 shares of the company’s stock were exchanged, compared to its average volume of 10,126,823. Tonix Pharmaceuticals has a twelve month low of $0.12 and a twelve month high of $22.14. The company has a fifty day moving average of $0.15 and a 200-day moving average of $1.49. The company has a market capitalization of $18.85 million, a price-to-earnings ratio of 0.00 and a beta of 2.06. The company has a current ratio of 1.15, a quick ratio of 0.72 and a debt-to-equity ratio of 0.13.

Analysts Set New Price Targets

Several research firms have recently weighed in on TNXP. StockNews.com initiated coverage on shares of Tonix Pharmaceuticals in a research note on Wednesday. They set a “sell” rating on the stock. Alliance Global Partners upped their price objective on Tonix Pharmaceuticals from $6.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, July 22nd.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.